Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Income from Continuing Operations (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Income from Continuing Operations data on record, last reported at 18891000.0 in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 7.0% to 18891000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 76116000.0, a 14824.71% decrease, with the full-year FY2025 number at 74880000.0, down 669.97% from a year prior.
  • Income from Continuing Operations reached 18891000.0 in Q1 2026 per FULC's latest filing, up from 20334000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for FULC hit a ceiling of 55409000.0 in Q2 2024 and a floor of 34070000.0 in Q2 2022.
  • A 5-year average of 18276588.24 and a median of 23738000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: surged 332.98% in 2024, then plummeted 131.22% in 2025.
  • Tracing FULC's Income from Continuing Operations over 5 years: stood at 26135000.0 in 2022, then increased by 5.28% to 24756000.0 in 2023, then skyrocketed by 33.07% to 16568000.0 in 2024, then fell by 22.73% to 20334000.0 in 2025, then increased by 7.1% to 18891000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for FULC at 18891000.0 in Q1 2026, 20334000.0 in Q4 2025, and 19595000.0 in Q3 2025.